NCT06078722RecruitingNot Applicable
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
Kazakh Association of Internal Medicine Specialists7 sites in 1 country264 target enrollmentStarted: February 8, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 264
- Locations
- 7
- Primary Endpoint
- Normalization of ALT levels during pathogenetic therapy for MAFLD at 12 months among study participants taking and not taking carnitine-orotate complex(COC) and biphenyl dimethyl dicarboxylate(BDD)
Study Overview
Brief Summary
The goal of this observational study is to learn the effectiveness and safety of the use of Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the pathogenetic therapy of metabolic-associated fatty liver disease (MAFLD)
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients of both sexes aged 18 to 75 years, who are citizens of the Republic of Kazakhstan;
- •Patients with a clinically and laboratory confirmed diagnosis of MAFLD, without severe concomitant diseases;
- •Patients who do not receive other adjuvant therapy (metabolic therapy drugs, essential phospholipids, ursodeoxycholic acid, glycyrrhizic acid, ademetionine and others);
- •Patients who have at least a 7-day gap between the end of other adjuvant therapy and the start of COC and BDD;
- •Patients who voluntarily signed the informed consent form.
Exclusion Criteria
- •Patients who abuse alcohol according to the AUDIT-c questionnaire;
- •Patients taking COC for more than 4 weeks before signing the informed consent;
- •Patients with contraindications to COC;
- •Patients diagnosed with diabetes mellitus;
- •Pregnancy and lactation;
- •Simultaneous use of levodopa, altretamine, cisplatin, statins;
- •Patients with coinfection with HIV, HBV, HCV;
- •Decompensated liver cirrhosis CPT≥7 points;
- •GFR ≤ 15 ml/min/1.73 m2;
- •Drug-induced liver damage;
- •Taking narcotic and psychotropic drugs;
- •Malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than >5 times;
- •patients with pronounced biochemical activity (ALT, AST more than 10 ULN) and total bilirubin more than 2 ULN;
- •Participation in an interventional clinical trial.
Outcomes
Primary Outcomes
Normalization of ALT levels during pathogenetic therapy for MAFLD at 12 months among study participants taking and not taking carnitine-orotate complex(COC) and biphenyl dimethyl dicarboxylate(BDD)
Time Frame: at 12 months
Secondary Outcomes
- Absolute and relative risks calculation of cardiovascular diseases developing when taking COC and BDD against the background of pathogenetic therapy for MAFLD, as well as comparison among study participants taking and not taking COC and BDD(up to 12 months since enrollment)
- Dynamics of carbohydrate metabolism parameters against the background of pathogenetic therapy for MAFLD among study participants taking and not taking COC and BDD(up to 12 months since enrollment)
- Dynamics of lipid metabolism parameters against the background of pathogenetic therapy for MAFLD among study participants taking and not taking COC and BDD(up to 12 months since enrollment)
- Assessment of adherence to COC and BDD therapy against the background of pathogenetic therapy for MAFLD in a cohort taking COC and BDD(up to 12 months since enrollment)
- Fibrosis level during pathogenetic therapy for MAFLD at 6 and 12 months among study participants taking and not taking COC and BDD(at 6 and 12 months)
- Normalization of ALT levels during pathogenetic therapy for MAFLD at 6 months among study participants taking and not taking COC and BDD(at 6 months)
- Steatosis level during pathogenetic therapy for MAFLD at 6 and 12 months among study participants taking and not taking COC and BDD(at 6 and 12 months)
- Frequency of registration of adverse and serious unexpected adverse events associated with the use of COC and BDD(up to 12 months since enrollment)
- Assessment of the impact of COC and BDD against the background of pathogenetic therapy for MAFLD on the quality of life of study participants taking and not taking COC and BDD(up to 12 months since enrollment)
- Absolute and relative risks calculation of type 2 diabetes mellitus developing when taking COC and BDD against the background of pathogenetic therapy for MAFLD, as well as comparison among study participants taking and not taking COC and BDD(up to 12 months since enrollment)
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Withdrawn
Not Applicable
Evaluation of the Effectiveness of the Complex of Carnitine Orotate and Biphenyl Dimethyl Dicarboxylate in the Adjuvant Therapy of Chronic Hepatitis D in Real Clinical Practice: a Prospective Cohort StudyChronic Viral Hepatitis B With Delta-AgentNCT06068140Kazakh Association of Internal Medicine Specialists
Completed
Phase 2
The Clinical Study of the Efficacy and Safety of L-Carnitine Injection in Treatment of Heart FailureHeart Failure,NCT01580553Lee's Pharmaceutical Limited268
Completed
Not Applicable
Investigation on the Efficacy of Oral Carnitine Challenge Test Based on a Gut Microbiota Functional TestDysbiosisHealthyNCT06175260National Taiwan University Hospital91
Enrolling By Invitation
Phase 3
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for EfficacyNon-Alcoholic Fatty Liver DiseaseNCT06152991Yoon Jun Kim196
Completed
Not Applicable
Investigation on the Effect of Carnitine Supplement on Gut Microbiota and TMAO Production CapacityDietary ExposureNCT02838732National Taiwan University Hospital56